Document is current
Any future updates will be listed below
-
Authors
Damotte, Diane
Warren, Sarah
Arrondeau, Jennifer
Boudou-Rouquette, Pascaline
Mansuet-Lupo, Audrey
Biton, Jérôme
Ouakrim, Hanane
Alifano, Marco
Gervais, Claire
Bellesoeur, Audrey
Kramkimel, Nora
Tlemsani, Camille
Burroni, Barbara
Duche, Angéline
Letourneur, Franck
Si, Han
Halpin, Rebecca
Creasy, Todd
Herbst, Ronald
Ren, Xing
Morel, Pascale
Cesano, Alessandra
Goldwasser, François
Leroy, Karen https://orcid.org/0000-0002-4379-0140
- License Information
-
More Information
Article History
Received: 1 July 2019
Accepted: 15 October 2019
First Online: 4 November 2019
Ethics approval and consent to participate
: This study was approved by the ethics committee (CPP Ile de France II, no. 2008-133, 2012 06-12, 2018 MS1) in agreement with article L.1121-1 of French law.
: Not applicable.
: This work was made possible by a collaborative research effort between the investigators at CERTIM and the investigators at NanoString. The CERTIM team (led by DD, FG, and KL) contributed samples and clinical information from their patient database, as well as performing the molecular characterizations including PD-L1 IHC, and running the nCounter assay. The NanoString team (SW, XR, PM, and AC) contributed reagents for the gene expression profiling, and performed analysis of the gene expression assays. Both groups contributed to the design of the analyses, interpretation of results, and preparation of the manuscript. RH, HS, RH and TC are full-time employees of MedImmune and they provided the tumor mutation burden assessment.
